Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.

NCT01640405 is registered in ClinicalTrials.gov with Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) as lead sponsor.

NCT NCT01640405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01640405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.
Lead sponsor
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2012
Completion date
November 30, 2018
Enrollment
350 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer